Last reviewed · How we verify
Xylometazoline 0,1%
Xylometazoline is a selective alpha-1 adrenergic receptor agonist that causes vasoconstriction of nasal blood vessels, reducing nasal congestion.
Xylometazoline is a selective alpha-1 adrenergic receptor agonist that causes vasoconstriction of nasal blood vessels, reducing nasal congestion. Used for Nasal congestion due to common cold, Nasal congestion due to allergic rhinitis, Nasal congestion due to sinusitis.
At a glance
| Generic name | Xylometazoline 0,1% |
|---|---|
| Also known as | Zymelin |
| Sponsor | Rigshospitalet, Denmark |
| Drug class | Alpha-1 adrenergic agonist (nasal decongestant) |
| Target | Alpha-1 adrenergic receptor |
| Modality | Small molecule |
| Therapeutic area | Otolaryngology / Respiratory |
| Phase | FDA-approved |
Mechanism of action
By stimulating alpha-1 adrenergic receptors on vascular smooth muscle in the nasal mucosa, xylometazoline induces vasoconstriction that decreases blood flow to nasal tissues and reduces swelling and congestion. This provides rapid symptomatic relief of nasal obstruction associated with colds, allergies, and sinusitis. The effect is topical and localized to the nasal cavity when administered as a nasal spray or solution.
Approved indications
- Nasal congestion due to common cold
- Nasal congestion due to allergic rhinitis
- Nasal congestion due to sinusitis
Common side effects
- Nasal irritation
- Sneezing
- Rebound congestion (with prolonged use)
- Headache
- Dizziness
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |